JP2011521967A5 - - Google Patents

Download PDF

Info

Publication number
JP2011521967A5
JP2011521967A5 JP2011511835A JP2011511835A JP2011521967A5 JP 2011521967 A5 JP2011521967 A5 JP 2011521967A5 JP 2011511835 A JP2011511835 A JP 2011511835A JP 2011511835 A JP2011511835 A JP 2011511835A JP 2011521967 A5 JP2011521967 A5 JP 2011521967A5
Authority
JP
Japan
Prior art keywords
immune
cells
target
immune system
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011511835A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011521967A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/045550 external-priority patent/WO2009146392A1/en
Publication of JP2011521967A publication Critical patent/JP2011521967A/ja
Publication of JP2011521967A5 publication Critical patent/JP2011521967A5/ja
Withdrawn legal-status Critical Current

Links

JP2011511835A 2008-05-29 2009-05-29 初代細胞由来生物製剤の作用機序 Withdrawn JP2011521967A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5692508P 2008-05-29 2008-05-29
US61/056,925 2008-05-29
PCT/US2009/045550 WO2009146392A1 (en) 2008-05-29 2009-05-29 Mechanism of action of primary cell derived biologic

Publications (2)

Publication Number Publication Date
JP2011521967A JP2011521967A (ja) 2011-07-28
JP2011521967A5 true JP2011521967A5 (enExample) 2012-11-01

Family

ID=41377590

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011511835A Withdrawn JP2011521967A (ja) 2008-05-29 2009-05-29 初代細胞由来生物製剤の作用機序

Country Status (7)

Country Link
US (1) US20110081313A1 (enExample)
EP (1) EP2296704A4 (enExample)
JP (1) JP2011521967A (enExample)
AU (1) AU2009251277A1 (enExample)
CA (1) CA2762314A1 (enExample)
MX (1) MX2010012985A (enExample)
WO (1) WO2009146392A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002034119A2 (en) 2000-10-27 2002-05-02 Immuno-Rx, Inc. Vaccine immunotherapy for immune suppressed patients
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
US20070025958A1 (en) * 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
EP2234642B8 (en) 2007-11-28 2017-11-01 IRX Therapeutics, Inc. Method of increasing immunological effect
CA2799081C (en) 2009-05-15 2018-10-30 Irx Therapeutics, Inc. Compositions comprising primary cell-derived biologics for enhancing immune responses in patients
AU2010328197B2 (en) 2009-12-08 2015-07-16 Irx Therapeutics, Inc. Method of reversing immune suppression of Langerhans cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667175B1 (en) * 1999-06-15 2003-12-23 The Trustees Of Columbia University Generation of antigen specific T suppressor cells for treatment of rejection
US20070031372A1 (en) * 2004-08-05 2007-02-08 Hadden John W Vaccine immunotherapy for immune suppressed patients
WO2002034119A2 (en) * 2000-10-27 2002-05-02 Immuno-Rx, Inc. Vaccine immunotherapy for immune suppressed patients
US20070025958A1 (en) * 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
EP1753452B1 (en) * 2004-06-04 2015-10-28 Cel-Sci Corporation A method for altering the cd4/cd8 ratio and the mononuclear cellular infiltrate into a tumor
WO2006047515A2 (en) * 2004-10-25 2006-05-04 Baylor Research Institute Dendritic cells loaded with heat shocked melanoma cell bodies
ITMI20051209A1 (it) 2005-06-27 2006-12-28 Tecnosanimed S R L Metodo per la predisposizione di set procedurali sterili di strumenti chirurgici per il servizio alle sale operatorie e trattamento di sanificazione tracciabile di sanificazione manutenzione confezionamento e sterilizzazione
AU2006292203A1 (en) * 2005-09-21 2007-03-29 Dask Technologies, Llc Methods and compositions for organ and tissue functionality
EP2234642B8 (en) 2007-11-28 2017-11-01 IRX Therapeutics, Inc. Method of increasing immunological effect

Similar Documents

Publication Publication Date Title
CL2013001602A1 (es) Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple.
HK1205453A1 (en) Methods of diagnosing and treating motor neuron diseases
JP2011521967A5 (enExample)
CL2013003341A1 (es) Un metodo y sistema para autenticar una sesion de un usuario.
JP2012143233A5 (enExample)
JP2011511805A5 (enExample)
JP2011136997A5 (enExample)
JP2007509067A5 (enExample)
JP2013005803A5 (enExample)
JP2013527965A5 (enExample)
JP2012500090A5 (enExample)
MX388743B (es) Conjugados oligonucleótido-péptido.
CL2014001070A1 (es) Compuestos derivados de aminoácidos funcionalizados en el n-terminal, capaces de formar micro- o nanopartículas para encapsular un agente; composición; uso para tratar enfermedades; y método de suministro de un polinucleótido a una célula.
WO2010037395A3 (en) Mhc multimers in cancer vaccines and immune monitoring
JP2015504870A5 (enExample)
HK1200321A1 (en) Bispecific immunobinders directed against tnf and il-17
JP2011522896A5 (enExample)
EA201001771A1 (ru) Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью
JP2014530840A5 (enExample)
JP2012030068A5 (enExample)
BRPI1008517A2 (pt) direcionamento duplo de mir-208 e mir-499 no tratamento de doenças cardíacas.
CL2012001999A1 (es) Material resistente a la formacion de biopelicula que comprende un agente activo compuesto esencialmente de un oxido de cobre insoluble a una concentracion de entre 3 y 10 % de dicho material resistente a la formacion de biopelicula; y metodo de prevencion, disminucion de incidencia formacion biopeliculas.
PL2859092T3 (pl) Szczepionka terapeutyczna do leczenia cukrzycy typu 1 u dzieci, zastosowanie sortera komórek oraz sposób namnażania komórek Treg do wytwarzania szczepionki do leczenia cukrzycy typu 1
SG11201600933QA (en) Application of andrographolide in the preparation of a pharmaceutical for treatment of inflammatory bowel disease, andrographolide enteric targeting micropellet, and method for preparation thereof
WO2013096732A3 (en) Methods of treating or preventing viral diseases by blocking interleukin-21